ChabioTech Appoints Hyunjeong Lee as President of R&D Division
[Asia Economy Reporter Lee Gwan-ju] Cha Biotech announced on the 14th that it has appointed Lee Hyun-jung, former CEO of Samyang Biopharm USA, as its new president. The newly appointed president will oversee the research and development (R&D) division of Cha Biotech and Cha Bio Group.
President Lee graduated from Yonsei University College of Medicine, completed her residency at Severance Hospital, and obtained certification as an obstetrics and gynecology specialist. She earned a master's degree in healthcare management from Harvard University in the United States.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
President Lee is a clinical development expert with 20 years of experience in new drug development in the global market. She has served as the global head of clinical development for oncology drugs at major global pharmaceutical companies including Pfizer Korea, Eli Lilly headquarters in the U.S., Baxalta, and Shire (now Takeda). From 2016 until last year, she served as Chief Strategy Officer and Chief Medical Officer of Samyang Biopharm, as well as CEO of Samyang Biopharm USA.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
